The abstract is read at the publisher; the summary is JClub's.
Semaglutide 2.4 mg weekly in adults with cardiovascular disease and BMI ≥27 shows consistent hazard ratios for the primary cardiovascular composite across frailty categories.
- Why it matters: It is uncertain whether frailty changes the benefit-risk balance of GLP-1 receptor agonists, so clinicians need evidence for efficacy and safety by baseline frailty status.
- What they did: In a post hoc analysis of the randomized SELECT trial (17 604 participants), frailty was quantified with a 31-item Rockwood cumulative deficit index and grouped by FI thresholds, then compared semaglutide versus placebo.
- The result: The primary outcome hazard ratios were 0.84 (95% CI, 0.65-1.07) for FI ≤0.210, 0.70 (0.59-0.82) for FI 0.211-0.310, and 0.92 (0.76-1.10) for FI ≥0.311 (P = .09 for interaction), with quality-of-life benefits larger at higher FI (P = .02).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.